The glutamine transporter protein appears to contribute to the survival of lung cancer cells, suggesting it may be a useful diagnostic biomarker and target for therapies.

New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.

Vanderbilt University has received a contract from the Centers for Medicare and Medicaid Services (CMS) for up to $28 million over four years to help more than 4,000 clinicians in the Southeast transform their clinical practices in ways that improve quality of patient care and hold down costs.

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

A new genetic model has generated new strategies for promoting tolerance to transplants – and improving long-term transplant outcomes – in the background of autoimmune disease.

Declining use of prescription painkillers among preoperative patients seeking joint replacements indicates efforts by the state of Tennessee to tighten the spigot on opioids are beginning to have an impact, according to a study by Vanderbilt’s Andrew Shinar, M.D.

Reduced-nicotine cigarettes were beneficial in reducing nicotine exposure and dependence, and also the number of cigarettes smoked per day, when compared with standard-nicotine cigarettes in a six-week study published in the New England Journal of Medicine.